The Drug Enforcement Administration (DEA) has scheduled an administrative hearing to get additional feedback from experts about its renewed push to ban two psychedelics after abandoning its original scheduling proposal in 2022. More than a year after DEA announced its intent to classify 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) as Schedule I drugs under the Controlled … Continue reading DEA Agrees To Hold Hearing On Proposed Ban Of Two Psychedelics Amid Pushback From Researchers